CervoMed Inc., a late clinical stage CNS company, presented its corporate overview, highlighting the development of neflamapimod, an oral drug targeting early-stage neurodegenerative diseases. Specifically focusing on Dementia with Lewy bodies $(DLB)$, the company emphasizes a significant commercial opportunity with a potential $5B US market. Neflamapimod, licensed from Vertex Pharmaceuticals, aims to address synaptic dysfunction in age-related neurological disorders and has received Fast Track designation from the FDA. CervoMed, which began trading on NASDAQ in August 2023, is headquartered in Boston, MA, and operates with a team of 15 full-time employees. The company has an experienced leadership team and has achieved proof-of-concept in DLB through successful phase 2 trials, with plans for a single phase 3 study to support NDA submission. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.